Person:
TAŞAN, ERTUĞRUL

Loading...
Profile Picture
Google ScholarScopusORCIDPublons
Status
Organizational Units
Organizational Unit
Job Title
First Name
ERTUĞRUL
Last Name
TAŞAN
Name
Email Address
Birth Date

Search Results

Now showing 1 - 10 of 14
  • PublicationMetadata only
    Does DRD2 polymorphism influence the clinical characteristics of prolactinoma?
    (2015-10-01) Ilhan, MAHMUT MUZAFFER; Kahraman, Ozlem Timirci; Turan, Saime; Turgut, SEDA; Karaman, Ozcan; Zeybek, Umit; SHUKUROV, Samir; Yaylim, Ilhan; Tasan, ERTUĞRUL; İLHAN, MAHMUT MUZAFFER; TURGUT, SEDA; KARAMAN, ÖZCAN; TAŞAN, ERTUĞRUL
    Objectives. - Genetic alterations explaining the clinical variability of prolactinomas still could not be clarified and dopamine D2 receptor (DRD2) polymorphism is a putative candidate for the variable response to dopaminergic treatment. The present study was conducted to investigate the influence of DRD2 TaqI A polymorphism on initial and follow-up characteristics of prolactinoma. Patients and methods. - Seventy-two patients with prolactinoma and 98 age and gender matched control subjects were recruited to the case-control study. Serum prolactin levels were assessed by enzyme-linked immunosorbent assay and DRD2 polymorphism was determined by polymerase chain reaction and restriction length polymorphism analysis. Results. - Decrease of prolactin levels and the tumor shrinkage after cabergoline treatment were 93.9 +/- 5.9% and 58.3 +/- 33.1% in microadenomas and 96.1 +/- 6.1% and 51.7 +/- 29.3 in macroadenomas (P = 0.02 and P > 0.05, respectively). We observed no significant difference for DRD2 genotypes and the alleles between the patients and healthy group (P > 0.05). Prolactin levels before treatment were correlated with tumor diameter before and after treatment and the percentage of prolactin decrease with treatment (P 0.05). Conclusion. - This study revealed that DRD2 TaqI A receptor polymorphism was not associated with the development of prolactinoma and its clinical characteristics. Future studies are needed to clarify the clinical implications of genetic alterations in prolactinoma. (C) 2015 Elsevier Masson SAS. All rights reserved.
  • PublicationMetadata only
    A novel AVP gene mutation in a Turkish family with neurohypophyseal diabetes insipidus
    (2016-03-01) Ilhan, MAHMUT MUZAFFER; Tiryakioglu, N. O.; KARAMAN, O.; Coskunpinar, E.; YILDIZ, R. S.; TURGUT, SEDA; Tiryakioglu, D.; TOPRAK, HÜSEYİN; TASAN, ERTUĞRUL; İLHAN, MAHMUT MUZAFFER; KARAMAN, ÖZCAN; TURGUT, SEDA; TOPRAK, HÜSEYİN; TAŞAN, ERTUĞRUL
    Purpose Familial neurohypophyseal diabetes insipidus (FNDI) is a rare, autosomal dominant, inherited disorder which is characterized by severe polydipsia and polyuria generally presenting in early childhood. In the present study, we aimed to analyze the AVP gene in a Turkish family with FNDI.
  • PublicationMetadata only
    Rapid improvement in visual loss with cabergoline treatment in a giant prolactinoma case: 5 years survey
    (2015-01-01T00:00:00Z) Tasan, ERTUĞRUL; HANIMOGLU, Hakan; Turgut, SEDA; Ilhan, MAHMUT MUZAFFER; EVRAN, Sevket; KAYNAR, Mehmet Yasar; TAŞAN, ERTUĞRUL; TURGUT, SEDA; İLHAN, MAHMUT MUZAFFER
    Giant prolactinoma is a rare subset of macroadenomas. Limited studies demonstrated which therapy could be successfully used in the first-line therapy of giant prolactinoma. We presented a case with a 54x40x40 mm pituitary adenoma and optic chiasmatic compression with left sphenoid sinus invasion. The tumor caused a loss of visual field of the right side. Cabergoline treatment was started with dose of 1.5 mg/week. Fifteen days later, the clinical visual acuity examination showed a significant improvement in the patient with visual field defect. After the five years follow-up magnetic resonance imagining showed reduction of the adenoma size (17x12 mm) was significant. Our findings suggest that, cabergoline can be used as a first-line therapy in giant prolactinomas because tumoral shrinkage without a surgical procedure and rapid improvement in visual field defect is achieved with this medical treatment.
  • PublicationMetadata only
    Kalıcı İmmunsupresyon Yapılmaksızın Paratiroit Allotransplantasyonu: 44 Olguluk Prospektif Klinik Seri
    (2016-11-01T00:00:00Z) Ayşan, Mustafa Erhan; Ercan, Cilem; Akbaş, Fahri; Kesgin Toka, Cemile; Özten Kandaş, Nur; Başoğlu, Harun; Taşçı, Yunus; Göncü, Beyza Servet; Özdemir, Burcu; Ersoy, Yeliz Emine; Taşan, Ertuğrul; Arıcı, Sema; Akçakaya, Adem; Kazancıoğlu, Rümeyza; AKBAŞ, FAHRİ; GÖNCÜ, BEYZA SERVET; ERSOY, YELIZ EMINE; TAŞAN, ERTUĞRUL; AKÇAKAYA, ADEM; KAZANCIOĞLU, RÜMEYZA
    Paratiroit allotransplantasyonu (PA-t) kalıcı hipoparatiroidili (KH) olgularda önemli ve görece yeni bir tedavi yöntemidir. Ancak donanımlı laboratuvar alt yapısı ile birlikte deneyimli ve multidisipliner bir ekip gerektirdiği için uygulanması güç bir süreçtir. Bu makalede Türkiye-de Sağlık Bakanlığından ruhsatlı ilk PA-t merkezinde yapılan, literatürdeki en geniş ikinci olgu serisini sunduk. Nakil için, bilgilendirilmiş onamı alınan, segonder hiperparatiroidisi olan kronik böbrek yetmezliği tanılı hastalardan alınan dokular kullanıldı. Bu dokulardan paratiroit hücreleri izole edildi, süspansiyon haline getirildi, 3-4 günlük kültür işleminden sonra KH tanısı olan 44 hastaya (12 erkek, 32 kadın, ortalama yaş: 44,5) transplante edildi. On gün süreyle, aşamalı olarak azalan dozlarda prednizolon uygulaması dışında kalıcı immunsupresyon yapılmadı. Ortalama 16 (1-26) aylık takipte, 32 (%72,7) hastada allograft fonksiyonu görüldü. Bu hastalarda oral ve/veya intravenöz kalsyum ve D vitamini desteği kesildi. Hiçbir hastada komplikasyon gözlenmedi. KH tanılı olguların tedavisinde kalıcı immunsupresyon yapılmaksızın PA-t, komplikasyon riski olmayan, etkin bir tedavi yöntemidir.
  • PublicationMetadata only
    Polycystic ovary syndrome is associated with P-wave prolongation and increased P-wave dispersion
    (2013-09-01) ERDOGAN, Ercan; AKKAYA, Mehmet; TURFAN, Murat; BATMAZ, Gonca; BACAKSIZ, AHMET; TASAL, Abdurrahman; Ilhan, Muzaffer; KUL, Seref; SONMEZ, Osman; VATANKULU, Mehmet Akif; Tasan, ERTUĞRUL; BACAKSIZ, AHMET; İLHAN, MAHMUT MUZAFFER; TAŞAN, ERTUĞRUL
  • PublicationMetadata only
    Graves- ophthalmopathy: the role of diffusion-weighted imaging in detecting involvement of extraocular muscles in early period of disease
    (2015-03-01) KILICARSLAN, R.; Alkan, ALPAY; ILHAN, M. M.; YETIS, H.; ARALASMAK, AYŞE; TASAN, ERTUĞRUL; ALKAN, ALPAY; İLHAN, MAHMUT MUZAFFER; ARALAŞMAK, AYŞE; TAŞAN, ERTUĞRUL
    Objective: To evaluate involvement of the extraocular muscle (EOM) using diffusion-weighted imaging (DWI), to determine whether there is correlation with conventional orbital MRI and apparent diffusion coefficient (ADC) values in patients with Graves- ophthalmopathy (GO).
  • PublicationMetadata only
    A Rare Cause of Back Pain after Pregnancy: Postpartum Osteoporosis and Treatment Approach
    (2016-12-01T00:00:00Z) Ilhan, Muzaffer; Cetin, Irem Yasin; Kurtulus, Duygu; KARAMAN, Özcan; TAŞAN, ERTUĞRUL; KARAMAN, ÖZCAN; TAŞAN, ERTUĞRUL
    Pregnancy associated osteoporosis (PAO) is a rare disease characterized by multiple vertebral compression fractures, limitation of movement and severe back pain. A positive family history of PAO, decreased body mass index, sedentary life style, smoking, malnutrition and low calcium intake are among the risk factors of this disease. PAO should be considered in patients with back pain during pregnancy and postpartum period. As a specified therapy option is lack for PAO, discontinuation of lactation and the supplementation of calcium and vitamin D are the main steps of the treatment in patients who are planning to become pregnant in the future. The current data show that bisphosphonates should be avoided and teriparatide may be a treatment option in patients who are planning to become pregnant. In this case report, it was aimed to highlight the diagnosis and treatment approaches of PAO in a patient with back pain during postpartum period.
  • PublicationMetadata only
    Parathyroid Carcinoma Case Report: Rapid Control of Refractory Hypercalcemia with Denosumab
    (2017-01-01) İLHAN, MAHMUT MUZAFFER; EKİNCİ, İSKENDER; KARAMAN, ÖZCAN; TURGUT, SEDA; TAŞAN, ERTUĞRUL; İLHAN, MAHMUT MUZAFFER; KARAMAN, ÖZCAN; TURGUT, SEDA; TAŞAN, ERTUĞRUL
  • PublicationMetadata only
    Association of PARP-1, NF-kappa B, NF-kappa BIA and IL-6, IL-beta 3 and TNF-alpha with Graves Disease and Graves Ophthalmopathy
    (2014-09-01T00:00:00Z) Niyazoglu, Mutlu; BAYKARA, Onur; Koc, Arzuhan; Aydogdu, Pinar; Onaran, Ilhan; Dellal, Fatma Dilek; TAŞAN, ERTUĞRUL; Sultuybek, Gonul Kanigur; TAŞAN, ERTUĞRUL
    Background: Graves Disease (GD) is an autoimmune disorder affected by an interaction of multiple genes such as Nuclear Factor-kappa B (NF-kappa B), Nuclear Factor-kappa B Inhibitor (NF-kappa BIA), Poly (ADP-ribose) polymerase-1 (PARP-1) and cytokines like Interleukin-1 beta (IL-1 beta), Interleukin-6 (IL-6) and Tumor Necrosis Factor-alpha (TNF-alpha) and mostly accompanied by an ocular disorder, Graves Ophthalmopathy (GO). We hypothesize that there is a relationship between GD, GO, polymorphisms of inflammatory related genes and their association with cytokines, which may play important roles in autoimmune and inflammatory processes.
  • PublicationMetadata only
    Electrocardiographic and echocardiographic evidence of myocardial impairment in patients with overt hypothyroidism
    (2013-12-01) ERDOGAN, Ercan; AKKAYA, Mehmet; Bacaksiz, AHMET; TASAL, Abdurrrahman; Ilhan, Muzaffer; KUL, Seref; ASOGLU, Emin; TURFAN, Murat; SONMEZ, Osman; Tasan, ERTUĞRUL; BACAKSIZ, AHMET; İLHAN, MAHMUT MUZAFFER; TAŞAN, ERTUĞRUL